1026422-80-9

Upstream product

• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 145485-77-4 3-t-butoxy-carbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-butanamide 
• 4879-95-2 4,4-dimethyl-azetidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 129765-95-3 3-[(tert-butoxycarbonyl)amino]-3-methylbutanoic acid 
• 124750-53-4 N-triphenylmethyl-5-(4'-methylbiphenyl-2-yl)tetrazole 
• 97278-68-7 3-azido-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepine 
• 155300-46-2 N-(tert-butoxycarbonyl)-4,4-dimethylazetidin-2-one 
• 86499-35-6 3-amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 137036-55-6 (R)-3-amino-2,3,4,5-tetrahydro-1H-[1]-benzazepin-2-one 

Relevant academic research and scientific papers

A novel 3-substituted benzazepinone growth hormone secretagogue (L- 692,429)

The 3-substituted benzazepinone, L-692,429 (compound 1), is the prototype compound of a novel class of compounds that stimulate release of growth hormone (GH). The molecule evolved from efforts to identify a non-peptide mimic of the growth hormone-releasing hexapeptide, GHRP-6. Compound 1 is prepared by sequential attachment of dimethyl-β-alanine and 2'- biphenylyltetrazole side chains to a chiral 3-aminobenzolactam nucleus. Comparison of the biological activity of 1 with the corresponding six- and eight-membered lactam analogs shows the seven-membered benzazepinone skeleton to be preferred. Molecular modeling of the structurally diverse GH secretagogues, L-692,429 and GHRP-6, was performed.